Trial Profile
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 19 Feb 2024
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Melphalan
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- Acronyms IRONCLAD
- 12 Dec 2023 Results(n=34 , (data as of 07/17/2023)) presented at the 65th American Society of Hematology Annual Meeting and Exposition, evaluating addition of ibrutinib to AutoHCT as part of conditioning and as consolidation therapy for pts with relapsed/refractory ABC-DLBCL
- 07 Oct 2023 Planned End Date changed from 14 Sep 2024 to 10 May 2024.
- 07 Oct 2023 Planned primary completion date changed from 7 Oct 2023 to 10 May 2024.